Loading...
skip to Main Content

International Liver Congress™ (ILC 2021)

OFFICIAL PRESS PROGRAMME

(as of MONDAY 14 JUNE 2021)

All Press conferences will be broadcast live for registered media and later uploaded here:

OFFICIAL PRESS CONFERENCE ABSTRACTS: ALL ORAL AND POSTER ABSTRACTS PRESENTED IN AN OFFICIAL PRESS CONFERENCE ARE EMBARGOED UNTIL THE TIME AND DATE OF THE START OF THE PRESS CONFERENCE IN WHICH THEY ARE DELIVERED.

Please note: Press programme subject to changes

TIME (EST / CET) THEME / TOPIC TIME OF PRESENTATIONS SPEAKERS
WEDNESDAY JUNE 23

09:00 EDT/15:00 CET

ILC 2021 Official Opening Press Conference: COVID-19 and Liver Disease Chair: Thomas Berg, Vice Secretary, EASL
Chronic liver disease and the risk of mortality after Covid-19: a national, retrospective, cohort study for 2020 (GS-1587) Thursday June 24

16:00-17:30 CET

Vincent Mallett, Medical Doctor, Assistance Publique-Hopitaux de Paris, France
Association of MAFLD with mortality in patients with COVID-19 in Mexico (PO-445) Wednesday June 23

15:00-15:45 CET

 

Martin Uriel Vázquez Medina, Researcher, Laboratory of Biomathematical and Biostatistical Modelling for Health,  Escuela Superior de Medicina, Mexico
Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients (PO-1449) Wednesday June 23

15:00-15:45 CET

Beatriz Mateos Muñoz, PhD Specialist in Gastroenterology and Hepatology Hospital Universitario Ramón y Cajal, University of Alcala, Spain
The alarming impact of the COVID-19 pandemic on alcohol related disease (PO-1099) Wednesday June 23

15:00-15:45 CET

Abdel-Aziz Shaheen, Assistant Professor, Department of Medicine and Community Health Sciences, Division of Gastroenterology and Hepatology, University of Calgary, Canada
Effect of COVID-19 on alcohol use disorder among hospitalised patients: a retrospective cohort control study (OA-1381) Saturday June 26

10:00-11:30 CET

Mohsan Subhani, Hepatology Ph.D fellow Nottingham University Hospitals NHS Trust and the University of Nottingham, UK
Elderly with advanced liver fibrosis had lower response to Pfizer-BioNtech´s SARS-CoV-2 vaccine. (OA- 2854) Saturday June 26

10:00-11:30 CET

Rifaat Safadi, Professor of Medicine, Hadassah-Hebrew University Hospital, Israel
TIME (EST / CET) THEME / TOPIC TIME OF PRESENTATIONS SPEAKERS
THURSDAY JUNE 24

09:00 EDT/15:00 CET

ILC 2021 Official Scientific Press Conference: Hepatitis, Acute on Liver Failure Chair: Tobias Böttler, EASL Scientific Committee

Speakers:

Modelling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress (LBP-2814) Thursday June 24

15:00-15:45 CET

Sarah Blach, HCV Group Leader, CDA Foundation, U.S.

 

Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results (OA-44) Friday June 25

14:00-15.30 CET

Edward Gane, Professor of Medicine at the

University of Auckland, New Zealand

Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR01 study (LBP-2730) Thursday June 24

15:00-15:45 CET

Heiner Wedemeyer, Professor and Chairman of the Department of Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover Medical Hospital, Germany
Hepatic arterial infusion chemotherapy in combination with PD-1 inhibitor aa conversion therapy in locally advanced, potentially resectable hepatocellular carcinoma: A Phase II study (OA- 2679) Friday June 25

14:00-15.30 CET

 

Li Xu, Director, Department of Liver Surgery, Sun Yat-sen University Cancer Centre, Guangzhou, China
A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE Liver Dialysis Device in patients with Acute on Chronic Liver Failure (ACLF) versus standard of care (SOC). (GS -1997) Thursday June 24

16:00-17:30

Banwari Agarwal, Consultant in Critical Care Medicin, Royal Free Hospital, United Kingdom
TIME (EST / CET) THEME / TOPIC TIME OF PRESENTATIONS SPEAKERS
FRIDAY JUNE 25

09:00 EDT/15:00 CET

ILC 2021 Official Scientific Press Conference: NAFLD/NASH Chair: Philip Newsome, Secretary-General EASL, UK
Food Insecurity is Associated with All-Cause Mortality in U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis (GS-1072) Thursday June 24

16:00-17:30 CET

 

Ani Kardashian, Assistant Professor of Clinical Medicine, Division of Gastrointestinal and Liver Diseases, University of Southern California, United States
ARO-HSD reduces hepatic HSD17B13 MRNA expression and protein levels in patients with suspected NASH (LBP-2580) Friday June 25

15:00-15:45 CET

Edward Gane, Professor of Medicine at the University of Auckland, New Zealand
Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial (LBP-2907) Friday June 25

15:00-15:45 CET

 

Arun Sanyal, Professor, Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, U.S.
Reduction in fibrosis and steatohepatitis imaging and biomarkers in a Phase III 52-week Resmetirom NASH trial (GS-2563) Friday June 25

16:00-17:30 CET

Stephen Harrison, Medical Director, Pinnacle Clinical Research, University of, Texas, U.S. & visiting professor of hepatology at the University of Oxford, UK
Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with non-alcoholic fatty liver disease (OA-555) Saturday June 26

10:00-11:30 CET

Jerome Boursier, Head of the Hepato-Gastroenterology Department, Angers University Hospital, France
Back To Top